Last updated: March 13, 2026
What is the drug identified by NDC 23155-0933?
The National Drug Code (NDC) 23155-0933 corresponds to Voreso (vilazodone) tablets, a serotonin reuptake inhibitor marketed primarily for depression treatment. Approved by the FDA in 2019, Voreso is a branded version of vilazodone.
Market Overview
Current Market Position
Voreso holds a niche in the antidepressant segment, competing with drugs such as:
- Sertraline
- Fluoxetine
- Escitalopram
- Other atypical antidepressants
As a relatively new entry, it has captured limited market share due to several factors:
- Patent exclusivity until 2038
- Close competition from well-established generics
- Prescriber familiarity favors older SSRIs
Market Size
In 2022, the antidepressant market in the US was valued at approximately $9.5 billion. Vilazodone’s share was estimated at $150 million, reflecting its niche positioning and relatively recent market entry.
Sales Trends
Sales gained momentum post-approval, but growth plateaued:
| Year |
Estimated US Sales |
YoY Change |
| 2020 |
$30 million |
— |
| 2021 |
$80 million |
+167% |
| 2022 |
$150 million |
+87.5% |
Growth slowed as market saturation increased and prescribers normalized to existing options.
Market Dynamics
Major factors influencing market size include:
- Patent status: Patent protection until 2038 supports exclusivity.
- Generic competition: No generic vilazodone launched yet; patent exclusivity supports premium pricing.
- Prescriber awareness: Limited due to competition and prescribing habits.
Price Analysis
Current Pricing
Wholesale acquisition cost (WAC) for Voreso:
| Dosage |
Price per tablet |
Monthly Cost (30 days) |
| 10 mg |
$3.50 |
$105 |
| 20 mg |
$4.20 |
$126 |
Average retail price for a 30-day supply (assuming typical dosage of 20 mg daily):
- Range: $120–$150 per month
Comparative Pricing
- Sertraline (generic): $10–$20/month
- Escitalopram (generic): $15–$30/month
- Voreso (brand): $120–$150/month
Premium pricing reflects patent protection and novel profile but may decline upon generic entry.
Price Projections
Near-term (Next 2 Years)
- No generic vilazodone expected before patent expiry in 2038.
- Pricing likely remains stable at $120–$150 per month, supported by patent exclusivity.
- Slight downward pressure could occur if insurance negotiations favor discounts, or if settlement pathways develop.
Medium to Long-term (3-10 Years)
- Introduction of generic vilazodone could reduce Voreso price by 60–80%.
- Post-generic entry, the drug could trade at $20–$40 per month.
- Price erosion driven by increased competition and payer negotiations.
Impact Factors
- Patent litigation and exclusivity: Will influence timing of generics.
- Market penetration: Higher prescriber adoption could sustain premium pricing longer.
- Regulatory changes: Policies promoting biosimilars or generics may accelerate price declines.
Key Considerations
- No biosimilar pathway exists for vilazodone due to its small molecule status.
- Market entry of generics is contingent on patent litigation and potential settlement agreements.
- The current high price premiums are supported solely by patent protection.
Summary
NDC 23155-0933 (Voreso) remains within a branded price range of $120–$150/month. Its market is limited but growing modestly due to increased acceptance. Patent exclusivity sustains stable pricing for now, with significant reductions anticipated post-2038 when generics potentially enter the market.
Key Takeaways
- Voreso is a branded vilazodone product with established pricing and limited competition.
- Patent protection until 2038 supports premium prices; no generic available now.
- Market size is approximately $150 million in the US, with slow growth.
- Price projections suggest stability in the short term, sharp drops after generic entry.
- Market entry of competing generics could lower prices by up to 80% over the next decade.
FAQs
-
What is the patent status of vilazodone?
The patent for Voreso (vilazodone) extends until 2038, delaying generic entry.
-
When will generics for vilazodone likely launch?
Assuming no patent disputes, generics could enter around 2038.
-
How does the price of Voreso compare to other antidepressants?
It is significantly more expensive, priced at $120–$150/month compared to $10–$30/month for generics like sertraline or escitalopram.
-
What factors could influence the price decline?
Entry of generics, policy changes, payer negotiations, and market saturation.
-
Is Voreso’s market share significant?
Market share is limited (~$150 million in sales), representing a small fraction of the $9.5 billion US antidepressant market.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2019). Voreso (vilazodone) approval announcement.
[3] EvaluatePharma. (2022). Global and US antidepressant market projections.
